No Data
No Data
No Data
No Data
No Data
Press Release: Lipella Pharmaceuticals Expands Its Advisory Board to Include Oncology Expertise
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise The new oncology committee will include: Jason Hafron, MD, DDS, PhD, MPH; and Pradeep Tyagi, PhD, MBA PITTSBURGH, Pa.
Dow JonesApr 17 20:00
Lipella Pharmaceuticals (LIPO.US) was first covered by Maxim Group and given a buy rating, with a target price of $2.00.
Lipella Pharmaceuticals (LIPO.US) was first covered by Maxim Group and given a buy rating, with a target price of $2.00.
Zhitong FinanceApr 9 23:40
Maxim Group Initiates Coverage On Lipella Pharmaceuticals With Buy Rating, Announces Price Target of $2
Maxim Group analyst Jason McCarthy initiates coverage on Lipella Pharmaceuticals with a Buy rating and announces Price Target of $2.
Analyst UpgradesApr 9 23:36
Lipella Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/09/2024 185.92% Maxim Group → $2 Initiates Coverage On → Buy
BenzingaApr 9 23:35
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our", "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant
GlobeNewswireApr 5 20:00
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
PITTSBURGH, April 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with
GlobeNewswireApr 3 20:00
No Data
No Data